This evidence suggests that, like the CXCR6-CXCL16 axis, TGF-β modulation could offer an opportunity to influence TRM behavior to promote systemic tumor immunity and control metastasis, especially when combined with other treatments. Here, CXCL16 is linked to neoplasm.